Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition

Transplantation

Volumn 91, Issue 11, 2011, Pages 1218-1226

  Walsh, R Carlin ^a   Brailey, Paul ^b   Girnita, Alin ^b   Alloway, Rita R ^b   Shields, Adele Rike ^a   Wall, Garth E ^d   Sadaka, Basma H ^d   Cardi, Michael ^c   Tevar, Amit ^a   Govil, Amit ^b   Mogilishetty, Gautham ^b   Roy Chaudhury, Prabir ^b   Woodle, E Steve ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CHRIST HOSPITAL   (United States)

^d Christ Hospital ^*

Author keywords

Antibody mediated rejection; Bortezomib; Donor specific antibody; Mixed acute rejection; Proteasome inhibition; Rituximab

Indexed keywords

BORTEZOMIB; DONOR SPECIFIC ANTIBODY; HLA ANTIBODY; HLA DQ ANTIGEN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANEMIA; ANTIBODY BLOOD LEVEL; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; COMPARATIVE STUDY; DIARRHEA; DRUG RESPONSE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOADSORPTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTOPENIA; VOMITING;

ACUTE DISEASE; ADULT; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMA CELLS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 79958245423     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318218e901     Document Type: Article

References (30)

1. Massy ZA, Guijarro C, Wiederkehr MR, et al. Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors. Kidney Int 1996; 49: 518.
2. Humar A, Kerr S, Gillingham KJ, et al. Features of acute rejection that increase risk for chronic rejection. Transplantation 1999; 68: 1200.
3. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: Impact on chronic rejection. Transplantation 1993; 55: 993.
4. Sipkens YW, Doxidis II, Mallat MJK, et al. Early versus late acute rejection episodes in renal transplantation. Transplantation 2004; 75: 204.
5. Kedainis RL, Koch MJ, Brennan DC, et al. Focal C4d- in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am J Transplant 2009; 9: 812.
6. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532.
7. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplantation 2009; 9: 2520.
8. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
9. Haririan A, Kiangkitiwan B, Kukuruga D, et al. The impact of c4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy.AmJ Transplant 2009; 9: 2758.
10. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
11. Everly JJ, Walsh RC, Alloway RR, et al. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009; 14: 662.
12. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277.
13. Walsh RC, Brailey P, Girnita A, et al. Woodle proteasome inhibitorbased antihumoral therapy: Differential response in early versus late antibody mediated rejection. Am J Transplant 2010; 10(suppl 4): 164.
14. Woodle ES, Light J, Rubin M, et al. Proteasome inhibitor therapy for antibody mediated rejection: Initial report from a multicenter collaborative. Am J Transplant 2010; 10(suppl 4): 83.
15. Eckman PM, Thorsgard M, Maurer D, et al. Bortezomib for refractory antibody-mediated cardiac allograft rejection. Clin Transpl 2009: 475.
16. Govil A, Walsh RC, Tevar A, et al. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients. Clinical Tranpslants 2009: 443.
17. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
18. Shapiro R, Basu A, Zeevi A, et al. Bortezomib rescue in refractory acute humoral rejection-Report of a case. Clin Transpl 2009: 431.
19. Hardinger KL, Alford K, Murillo D. Bortezomib for acute humoral rejection in two repeat transplant recipients. Clin Transpl 2009; 479.
20. Djamali A, Buth BL, Torrealba J, et al. Bortezomib as a rescue therapy for hyperacute and multi-drug resistant mixed acute rejection after kidney transplantation. Clin Transpl 2009; 485.
21. Sun Q, Liu ZH, Ji S, et al. Late and early C4d-positive acute rejection: Different clinico-histopathological subentities in renal transplantation. Kidney Int 2006; 70: 377.
22. Lefaucheur C, Nochy D, Hill GS, et al. Determinants of poor graft outcome in patients with antibody-mediated rejection. Am J Transplant 2007; 7: 832.
23. Pefaur J, Diaz P, Panace R, et al. Early and late humoral rejection: A clinicopathologic entity in two times. Transplant Proc 2008; 40: 3229.
24. Lerut E, Kuypers DR, Verbaken E, et al. Acute rejection in noncompliant renal allograft recipients: A distinct morphology. Clin Transplant 2007; 21: 344.
25. Bonvini P, Zorzi E, Basso G, et al. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia 2007; 21: 838.
26. Amanna IJ, Carlson NE, Slitkin MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357: 1903.
27. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.
28. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033.
29. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247.
30. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ docs/ctcaev3.pdf. Accessed March 15, 2011.